Physician profile
David C Williams
NPI 1518991264
$6,351.73
in general payments reported to CMS, 2019-2025
22 companies · $625 in 2025
The $625 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2021: $42.33 · 2022: $192 · 2023: $4,416 · 2024: $774 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,753 · Food and Beverage: $1,957 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,752.50 |
| Food and Beverage | $1,957.03 |
| Education | $106.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $4,083.26 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $701.71 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $290.73 | 2024-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $246.78 | 2021-2025 | |
| Travere Therapeutics, INC. | $202.32 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $126.41 | 2019-2024 | Jynarque |
| Impulse Dynamics (USA) INC. | $118.83 | 2024-2025 | Optimizer |
| Horizon Therapeutics Plc | $81.97 | 2019-2023 | Krystexxa |
| Akebia Therapeutics INC | $61.81 | 2019-2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $55.74 | 2024 | Ibsrela |
| Novo Nordisk INC | $55.31 | 2024-2025 | Rybelsus, Ozempic, Rivfloza |
| Cormedix INC. | $53.63 | 2025 | Defencath |
| Pharmacosmos Therapeutics INC. | $45.33 | 2025 | Monoferric |
| Baxter Healthcare | $43.78 | 2023 | |
| Lilly USA, LLC | $39.72 | 2024 | Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $25.63 | 2025 | Empaveli |
| Calliditas Therapeutics US INC. | $22.96 | 2022 | |
| Daiichi Sankyo INC. | $22.94 | 2019 | |
| Mallinckrodt Enterprises LLC | $21.12 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.60 | 2023 | |
| Glaxosmithkline, LLC. | $19.08 | 2024 | Benlysta |
| Amag Pharmaceuticals, INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.